Welcome to our dedicated page for ACACIA RESEARCH SEC filings (Ticker: ACTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACACIA RESEARCH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACACIA RESEARCH's regulatory disclosures and financial reporting.
ACACIA RESEARCH CORP (ACTG) director Maureen O'Connell reported selling a total of 33,000 shares of ACTG common stock in open market or private transactions. On September 2, 2026, she sold 20,534 shares at a weighted average price of $4.63 per share, in multiple trades between $4.615 and $4.645. On September 3, 2026, she sold 12,466 shares at a weighted average price of $4.57 per share, in multiple trades between $4.51 and $4.66. No Rule 10b5-1 trading plan is reported, and post-transaction share holdings are not stated.
Acacia Research Corporation (ACTG) is the issuer of common stock for which director Maureen E. O'Connell has filed a notice under Rule 144 to sell up to 33,000 shares through UBS Financial Services Inc. The shares relate to RSU vestings on May 12, 2022 and May 26, 2024 and are planned for sale on or after September 2, 2026. The filing also lists a prior sale of 10,000 shares in the past three months.
ACACIA RESEARCH CORP (ACTG) director Michelle Felman reported two bona fide gift transactions of ACTG common stock on August 28, 2026. In total, she gifted 32,172 shares, at a reported reference value of $4.49 per share, to an irrevocable trust established for the benefit of her son, for no consideration.
ACACIA RESEARCH CORP (ACTG) director Maureen O'Connell reported selling 10,000 shares of ACTG common stock on 2026-08-19 in an open-market transaction. The weighted average sale price was $4.60 per share, with individual trades between $4.57 and $4.63. Following this sale, she directly holds 287,655 shares of ACTG common stock.
Acacia Research Corporation (ACTG) director Maureen E. O'Connell filed a Rule 144 notice to sell up to 10,000 shares of ACTG common stock through UBS Financial Services Inc. The shares relate to RSU vesting on 05/26/2024, with the proposed sale by 08/19/2026 on NASDAQ.
Acacia Research Corp director Isaac T. Kohlberg reported an open-market sale of 32,188 shares of ACTG common stock on 2026-08-12. The shares were sold at a weighted average price of $4.67 per share, with individual trades executed between $4.66 and $4.69. Following this transaction, Kohlberg directly holds 78,310 ACTG shares. The filing does not indicate that the sale was made under a Rule 10b5-1 trading plan.
Acacia Research Corporation (ACTG) has a notice from an affiliate indicating an intention to sell up to 32,188 shares of common stock, with an aggregate market value of $150,199.00, on or after August 12, 2026 on the Nasdaq Global Select Market.
The filing also lists prior issuances of restricted stock by the issuer for services rendered, including 30,534 shares granted on May 26, 2023 and 32,172 shares granted on May 30, 2025.
An affiliate of ACTG filed notice of a proposed disposition of common stock. The plan covers up to 85,827 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an approximate aggregate market value of $395,181.84 and an approximate sale date of August 11, 2026. The shares relate to restricted stock grants dated May 26, 2024, June 7, 2025, and May 30, 2026.
Acacia Research Corporation operates a diversified portfolio of intellectual property, industrial printing, energy and manufacturing businesses, supported by a strategic relationship with Starboard Value and significant patent licensing activities.
For the six months ended June 30, 2026, total revenues were 168,801 (in thousands), slightly below 175,659 (in thousands) a year earlier. Net loss attributable to Acacia was 15,694 (in thousands), versus net income of 20,994 (in thousands) in 2025, driven largely by a 30,934 impairment of its MalinJ1 equity method investment and weaker operating income. Basic and diluted net loss per common share were 0.16. Cash and cash equivalents were 307,635 (in thousands) and total assets 791,529 (in thousands) as of June 30, 2026. Q2 2026 showed strong intellectual property revenues of 60,913 (in thousands) and energy revenues of 20,545 (in thousands), while industrial and manufacturing revenues were modestly lower. Operating cash flow for the first half declined to 7,307 (in thousands), reflecting working-capital swings and the timing of licensing receipts.
Acacia Research Corporation reported strong operating results for the quarter ended June 30, 2026, with total revenue of $114.6 million, up 124% from $51.2 million in the prior-year quarter. Growth was led by Intellectual Property Operations, which generated revenue of $60.9 million, and Benchmark Energy, which posted its strongest quarter under Acacia with revenue of $20.5 million.
GAAP net income for the quarter was $47 thousand, or $0.00 diluted EPS, while Adjusted Net Income was $12.8 million, or $0.13 Adjusted Diluted EPS. Total Company Adjusted EBITDA was $17.3 million, compared to $1.9 million in the prior-year quarter, and Operated Segment Adjusted EBITDA reached $22.8 million. Results included a $30.9 million impairment of the MalinJ1 equity method investment in 2026.
Liquidity remained significant, with cash, cash equivalents, equity securities measured at fair value and loans receivable totaling $334.6 million, or $3.43 per share, and no parent-company debt. Consolidated non-recourse indebtedness at Benchmark and Deflecto was $90.4 million. Book value was $557.0 million with 97.6 million shares outstanding, or $5.71 per share.